Rhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome.

IF 0.8 4区 医学 Q4 HEMATOLOGY
Mohammad Alzoubi, Adam Diab, Nada Odeh, Noor Al-Assaf, Shrouq Amer, Raghad Darweesh, Ahmad Kh Ibrahimi, Mohammad Boheisi, Iyad Sultan, Hadeel Halalsheh
{"title":"Rhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome.","authors":"Mohammad Alzoubi, Adam Diab, Nada Odeh, Noor Al-Assaf, Shrouq Amer, Raghad Darweesh, Ahmad Kh Ibrahimi, Mohammad Boheisi, Iyad Sultan, Hadeel Halalsheh","doi":"10.1097/MPH.0000000000003124","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.</p><p><strong>Methods: </strong>We reviewed retrospectively children younger than 2 years with newly diagnosed RMS treated from January 2002 until December 2022 at King Hussein Cancer Center. Demographics, clinical characteristics, and outcomes were analyzed. Statistical analysis included descriptive statistics and survival analysis using Kaplan-Meier methods. All cases were reviewed in a multidisciplinary clinic comprising experienced radiotherapists and surgeons.</p><p><strong>Results: </strong>We identified 34 cases of RMS in patients younger than 2 years at diagnosis. The median age was 13 months, with 70.6% males. The most common tumor site was bladder/prostate (N=13, 38%), followed by orbit (N=5, 14.7%), the predominant subtype was embryonal (N=30). Risk-stratification categorized 17.6% as low-risk and 79.4% as intermediate-risk. Twenty-five patients had tumors >5 cm, with metastasis in 6 (17.6%). All patients received neo-adjuvant chemotherapy, local control was by radiotherapy only (n=12, 35.3%), combined surgery and radiotherapy (n=11, 32.4%), or surgery alone (n=3, 8.8%). The 5-year event-free and overall survival rates were 55.1% and 57.5%, respectively. Fourteen patients experienced relapse/progression, with local relapse the most common pattern. TNM stage, clinical group, metastasis at diagnosis, and radiotherapy use significantly impacted survival.</p><p><strong>Conclusions: </strong>Children under 2 years of age with RMS face significant challenges, with high local recurrence rates and suboptimal survival outcomes compared with older pediatric patients. Our findings highlight the need for tailored treatment approaches that balance effective local control with minimizing long-term toxicity.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPH.0000000000003124","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.

Methods: We reviewed retrospectively children younger than 2 years with newly diagnosed RMS treated from January 2002 until December 2022 at King Hussein Cancer Center. Demographics, clinical characteristics, and outcomes were analyzed. Statistical analysis included descriptive statistics and survival analysis using Kaplan-Meier methods. All cases were reviewed in a multidisciplinary clinic comprising experienced radiotherapists and surgeons.

Results: We identified 34 cases of RMS in patients younger than 2 years at diagnosis. The median age was 13 months, with 70.6% males. The most common tumor site was bladder/prostate (N=13, 38%), followed by orbit (N=5, 14.7%), the predominant subtype was embryonal (N=30). Risk-stratification categorized 17.6% as low-risk and 79.4% as intermediate-risk. Twenty-five patients had tumors >5 cm, with metastasis in 6 (17.6%). All patients received neo-adjuvant chemotherapy, local control was by radiotherapy only (n=12, 35.3%), combined surgery and radiotherapy (n=11, 32.4%), or surgery alone (n=3, 8.8%). The 5-year event-free and overall survival rates were 55.1% and 57.5%, respectively. Fourteen patients experienced relapse/progression, with local relapse the most common pattern. TNM stage, clinical group, metastasis at diagnosis, and radiotherapy use significantly impacted survival.

Conclusions: Children under 2 years of age with RMS face significant challenges, with high local recurrence rates and suboptimal survival outcomes compared with older pediatric patients. Our findings highlight the need for tailored treatment approaches that balance effective local control with minimizing long-term toxicity.

2岁以下儿童横纹肌肉瘤:临床特征和结果。
背景:1 - 9岁儿童横纹肌肉瘤(Rhabdomyosarcoma, RMS)通常对综合治疗反应良好,预后良好。然而,由于考虑到手术/放射的长期影响,婴儿可能会因为接受较少的积极的局部治疗而病情恶化。本研究探讨2岁以下儿童RMS的临床特点、治疗方法和生存结局。方法:我们回顾性回顾了2002年1月至2022年12月侯赛因国王癌症中心治疗的2岁以下新诊断的RMS患儿。分析了人口统计学、临床特征和结果。统计分析包括描述性统计和Kaplan-Meier法的生存分析。所有病例均在由经验丰富的放射治疗师和外科医生组成的多学科诊所进行复查。结果:我们确定了34例诊断时年龄小于2岁的RMS患者。年龄中位数为13个月,男性占70.6%。最常见的肿瘤部位为膀胱/前列腺(N=13, 38%),其次为眼眶(N=5, 14.7%),主要亚型为胚胎型(N=30)。风险分层将17.6%归为低风险,79.4%归为中风险。25例患者肿瘤直径达5 cm, 6例(17.6%)发生转移。所有患者均接受新辅助化疗,局部对照仅放疗(n=12, 35.3%)、手术与放疗联合(n=11, 32.4%)或单纯手术(n=3, 8.8%)。5年无事件生存率和总生存率分别为55.1%和57.5%。14例患者出现复发/进展,以局部复发最常见。TNM分期、临床分组、诊断时是否有转移、是否使用放疗对生存率有显著影响。结论:2岁以下的RMS儿童面临着巨大的挑战,与大龄儿童患者相比,其局部复发率高,生存结果不理想。我们的研究结果强调需要量身定制的治疗方法,以平衡有效的局部控制和最小化长期毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
8.30%
发文量
415
审稿时长
2.5 months
期刊介绍: ​Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信